Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-659 + Ixazomib in R/R AML
NCT04079738Phase 2Terminated
- Start
- Sep 2019
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of mivavotinib in acute myeloid leukemia (AML) (2 arms). Primary endpoints: Maximum Tolerated Dose and Overall Response Rate. Started Sep 2019; status: terminated.
02
Drugs
mivavotinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04079738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04079738.